The effects of NT1014, a novel AMPK activator, compared to metformin, on ovarian cancer cell proliferation, apoptosis, and tumor growth

Wysham, Weiya

42
The effects of NT1014, a novel AMPK activator, compared to metformin, on ovarian cancer cell proliferation, apoptosis, and tumor growth

Monday, March 30, 2015: 10:47 AM

Continental Ballroom (Hilton Chicago)

W. Z. Wysham¹, J. E. Kilgore², A. L. Jackson³, H. Qiu¹, C. Zhou¹, K. W. Batchelor⁴ and V. L. Bae-Jump¹
¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²Houston Methodist Hospital, Houston, TX, ³University of Cincinnati, Cincinnati, OH, ⁴NovaTarg Therapeutics, Research Triangle Park, NC

2015 Annual Meeting on Women's Cancer®

March 26 - 31, 2015

Navigation

42
The effects of NT1014, a novel AMPK activator, compared to metformin, on ovarian cancer cell proliferation, apoptosis, and tumor growth

42 The effects of NT1014, a novel AMPK activator, compared to metformin, on ovarian cancer cell proliferation, apoptosis, and tumor growth

42
The effects of NT1014, a novel AMPK activator, compared to metformin, on ovarian cancer cell proliferation, apoptosis, and tumor growth